Previous 10 | Next 10 |
ADMA Biologics, Inc. (ADMA) Q4 2019 Earnings Conference Call March 12, 2020, 16:30 ET Company Participants Samuel Martin - Argot Partners Adam Grossman - Co-Founder, President, CEO & Director Brian Lenz - EVP & CFO Conference Call Participants Anthony Petrone - Jeff...
ADMA Biologics (NASDAQ: ADMA ): Q4 GAAP EPS of -$0.18 in-line. More news on: ADMA Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Achieved Fourth Quarter 2019 Total Revenues of $12.0 Million, a 197% Increase Over Fourth Quarter 2018 Achieved Full Year 2019 Total Revenues of $29.3 Million, a 73% Increase Over Full Year 2018 Strengthened Balance Sheet Through Successful Completion of Underwritten Public...
Dynatronics (NASDAQ: DYNT ) +224% . More news on: Dynatronics Corporation, Altimmune, Inc., Allied Healthcare Products, Inc., Stocks on the move, , Read more ...
ADMA Biologics (NASDAQ: ADMA ) has fully exercised underwriters’ over-allotment option of an additional ~3.5M common shares at $3.50 per share, for gross proceeds of ~$12.3M, bringing the total gross proceeds to ~$94.6M. More news on: ADMA Biologics, Inc., Healthcare stocks n...
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of im...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Gainers: ADMS +14.9% . SALT +7.7% . MGI +3.6% . ADMA +3.5% . AKAM +3.2% . More news on: Adamas Pharmaceuticals, Inc., Scorpio Bulkers Inc., MoneyGram International, Inc., Stocks on the move, , , News on ETFs Read more ...
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients ...
After announcing it had priced an up-sized secondary offering of its shares at $3.50 per share, ADMA Biologics (NASDAQ: ADMA) shares tumbled 13.5% at 12:15 p.m. EST on Friday. A commercial-stage biotech company , ADMA Biologics markets Bivigam and Asceniv, two plasma-derived, polyclonal, i...
News, Short Squeeze, Breakout and More Instantly...
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly fina...
U.S. stocks were mostly higher, with the Dow Jones gaining over 100 points on Friday. Shares of Genpact Limited (NYSE:G) rose sharply during Friday...
ADMA Biologics, Inc. (NASDAQ:ADMA) reported better-than-expected first-quarter financial results and issued strong revenue guidance on Thursday. AD...